診斷放射性同位素市場報告：趨勢、預測和競爭分析（至 2031 年）

全球診斷放射性同位素市場未來前景光明，在醫院、專科診所、診斷中心、學術和研究機構市場都機會。預計到 2031 年全球診斷放射性同位素市場規模將達到 69 億美元，2025 年至 2031 年的複合年成長率為 6.7%。該市場的關鍵促進因素是對疾病早期和準確診斷的需求不斷成長、診斷顯像模式的進步以及對α發射同位素的需求不斷成長。

• Lucintel 預測，基於放射性同位素的Technetium-99m 部分將在預測期內經歷最高的成長。
• 在最終用途類別中，預計專科診所將在預測期內見證最高成長。
• 按地區分類，北美將在預測期內繼續成為最大的地區。

診斷放射性同位素市場的策略性成長機會

由於技術、生產和診斷技術的進步，診斷放射性同位素市場為關鍵應用提供了多種策略成長機會。

• PET 影像在腫瘤學中的擴展：PET 影像在癌症診斷中的廣泛應用代表著一個巨大的成長機會。擴大 PET 放射性同位素的使用範圍將改善早期癌症的檢測和治療計劃。
• 混合成像技術的發展：對混合 PET-CT 和 PET-MRI 技術的投資將透過提供更精確的診斷工具提供成長機會。這些系統使醫療保健提供者能夠提高癌症和心血管疾病等複雜疾病的診斷準確性。
• 非鈾同位素產量增加：非鈾基診斷同位素的生產具有成長潛力。開發這些技術有助於緩解環境問題並提供更永續和可靠的同位素供應。
• 擴展到新興市場：擴大新興市場的醫療保健基礎設施，特別是亞洲和拉丁美洲，為擴大診斷放射性同位素的生產和取得提供了機會。此次擴展將有助於解決醫療保健不平等問題並提高服務不足地區的診斷能力。
• 投資低劑量成像技術：減少輻射暴露的放射性同位素成像技術的開發代表著一個成長機會。這些創新將使診斷成像更加安全，並鼓勵其廣泛應用於更早、更頻繁的診斷。

這些策略性成長機會凸顯了診斷放射性同位素領域的技術創新和市場擴張的潛力。專注於 PET 成像、混合系統、非鈾同位素生產、新興市場和低劑量技術將使公司推動成長並改善患者的治療效果。

診斷放射性同位素市場促進因素與挑戰

診斷放射性同位素市場受到各種促進因素​​和挑戰的影響，這些促進因素和挑戰決定了其成長和發展。了解這些因素對於有效駕馭市場至關重要。

推動診斷放射性同位素市場的因素有：

• 早期疾病檢測需求不斷增加：對癌症和心血管疾病等疾病早期檢測的重視程度不斷提高，推動了對診斷放射性同位素的需求，尤其是 PET 和 SPECT 同位素。
• 成像技術的進步：混合系統和人工智慧整合等成像技術的創新正在提高診斷的準確性並鼓勵進一步採用基於放射性同位素的診斷方法。
• 全球老化：隨著全球人口老化，慢性病盛行率增加，推動了依賴放射性同位素進行早期檢測和監測的診斷影像的需求。
• 增加政府支持：世界各國政府都在投資核子醫學研究和放射性同位素生產，以確保診斷同位素的穩定供應，特別是在努力實現醫療自給自足的國家。
• 擴大非鈾生產的使用：受環境問題和確保Technetium-99m等關鍵同位素穩定供應鏈的願望的推動，向非鈾基同位素生產的轉變正在獲得動力。

診斷放射性同位素市場的挑戰包括：

• 放射性同位素生產成本高：生產診斷放射性同位素的成本過高，尤其是透過迴旋加速器生產等先進方法，這可能會限制某些地區的取得並影響市場擴張。
• 供應鏈中斷：診斷同位素的全球供應鏈可能脆弱，生產中斷可能影響Technetium-99m等關鍵同位素的可得性，導致診斷程序延遲。
• 監管障礙：對放射性同位素的生產、處理和處置的嚴格監管要求可能會減緩市場成長，尤其是在核能法規複雜的地區。

診斷放射性同位素市場受到技術進步、對早期檢測疾病的需求不斷成長以及政府支持不斷增加的推動。但他們也必須應對生產成本上升、供應鏈中斷、監管障礙以及新興市場進入限制等問題。平衡這些市場促進因素和挑戰是維持市場成長的關鍵。

目錄

第1章執行摘要

第 2 章。

• 簡介、背景和分類
• 供應鏈
• 產業促進因素與挑戰

第 3 章 市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）與預測（2025-2031）
• 全球診斷放射性同位素市場趨勢（2019-2024 年）及預測（2025-2031 年）
• 全球診斷放射性同位素市場（以放射性同位素分類）
  • Technetium-99m
  • 鉈-201
  • 鎵-67
  • 碘-123
  • FDG
  • 銣 82
  • 其他
• 全球診斷放射性同位素市場（以顯像模式）
  • SPECT
  • PET
  • 貝塔發射體
• 全球診斷放射性同位素市場（按應用）
  • 診斷
  • 治療
• 全球診斷放射性同位素市場（按最終用途分類）
  • 醫院
  • 專科門診
  • 診斷中心
  • 學術研究所
  • 其他

第 4 章區域市場趨勢與預測分析（2019-2031 年）

• 全球診斷放射性同位素市場（按地區）
• 北美診斷放射性同位素市場
• 歐洲診斷放射性同位素市場
• 亞太地區診斷放射性同位素市場
• 世界其他地區診斷放射性同位素市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球診斷放射性同位素市場成長機會（以放射性同位素）
  • 全球診斷放射性同位素市場按顯像模式分類的成長機會
  • 全球診斷放射性同位素市場成長機會（按應用）
  • 全球診斷放射性同位素市場成長機會（按最終用途分類）
  • 全球診斷放射性同位素市場各區域成長機會
• 全球診斷放射性同位素市場的新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球診斷放射性同位素市場的產能
  • 全球診斷放射性同位素市場的企業合併
  • 認證和許可

第7章主要企業簡介

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler

The future of the global diagnostic radioisotope market looks promising with opportunities in the hospital, specialty clinic, diagnostic center, and academic & research institute markets. The global diagnostic radioisotope market is expected to reach an estimated $6.9 billion by 2031 with a CAGR of 6.7% from 2025 to 2031. The major drivers for this market are the increasing demand for early and accurate diagnosis of diseases, growing advancements in diagnostics imaging modalities, and expanding demand for alpha radioisotopes.

• Lucintel forecasts that, within the radioisotope category, the technetium-99m segment is expected to witness the highest growth over the forecast period.
• Within the end use category, specialty clinic is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Diagnostic Radioisotope Market

The diagnostic radioisotope market is evolving, driven by advancements in technology, improved production methods, and increased demand for precise diagnostic tools in healthcare.

• Growing Demand for PET Imaging: The use of PET imaging is expanding due to its effectiveness in detecting cancer and neurological disorders. This trend is increasing the demand for PET radioisotopes like FDG, which are essential for accurate diagnosis.
• Non-Uranium-Based Production: There is a growing shift toward non-uranium-based methods for producing diagnostic radioisotopes. These methods are safer and more sustainable, reducing environmental concerns while ensuring a reliable supply for medical use.
• Hybrid Imaging Systems: The integration of PET with CT or MRI is becoming more common, offering improved diagnostic accuracy. This trend is reshaping diagnostic practices, particularly in cancer, cardiovascular, and neurological imaging.
• Focus on Reducing Radiation Exposure: New advancements aim to reduce the radiation dose patients receive during diagnostic procedures. This trend improves patient safety, making radioisotope-based imaging a more appealing option for frequent and early-stage diagnostics.
• Increased Self-Sufficiency in Production: Countries are focusing on becoming self-sufficient in radioisotope production to avoid supply chain disruptions. This trend is driving investments in local facilities and technologies to produce essential diagnostic isotopes domestically.

These trends are reshaping the diagnostic radioisotope market by enhancing diagnostic capabilities, improving safety, and addressing global supply chain concerns. The growing use of PET imaging, hybrid systems, and sustainable production methods is driving innovation and expanding the market's reach.

Recent Developments in the Diagnostic Radioisotope Market

Key developments in the diagnostic radioisotope market reflect technological advancements and strategic investments aimed at improving isotope availability and diagnostic accuracy.

• Non-Uranium Production Methods: The adoption of non-uranium-based production for Technetium-99m is reducing reliance on uranium, ensuring a more sustainable supply chain, and improving global access to this critical diagnostic isotope.
• Expansion of PET Isotope Production: Countries like China and India are increasing PET isotope production, particularly FDG, which is essential for cancer diagnostics. These developments are helping to meet the rising demand for PET imaging in oncology.
• Development of Hybrid Imaging Systems: The introduction of hybrid PET-CT and PET-MRI systems in countries like Germany is enhancing diagnostic precision, particularly in complex cases such as cancer metastasis, cardiovascular disease, and neurological disorders.
• Collaborative Research and Production: In India, collaborations between hospitals and research institutions are improving access to diagnostic radioisotopes, particularly in underserved regions. These partnerships aim to address healthcare inequalities and enhance diagnostic services.
• Reduction in Radiation Dose: Japan is at the forefront of reducing radiation exposure in radioisotope imaging, focusing on innovations that maintain image quality while minimizing the risks associated with radiation.

These developments are advancing the diagnostic radioisotope market by improving production methods, enhancing diagnostic precision, and making radioisotope imaging safer and more accessible. The focus on sustainability, technological innovation, and collaboration is driving growth in the market.

Strategic Growth Opportunities for Diagnostic Radioisotope Market

The diagnostic radioisotope market offers several strategic growth opportunities across key applications, driven by advancements in technology, production, and diagnostic techniques.

• Expansion of PET Imaging in Oncology: The increasing use of PET imaging for cancer diagnostics presents a major growth opportunity. Expanding access to PET radioisotopes can improve early cancer detection and treatment planning.
• Development of Hybrid Imaging Technologies: Investing in hybrid PET-CT and PET-MRI technologies offers growth opportunities by providing more precise diagnostic tools. These systems enable healthcare providers to improve accuracy in diagnosing complex conditions like cancer and cardiovascular disease.
• Increased Production of Non-Uranium Isotopes: There is potential for growth in the production of non-uranium-based diagnostic isotopes. Developing these technologies can reduce environmental concerns and provide a more sustainable and reliable isotope supply.
• Expansion into Emerging Markets: Growing healthcare infrastructure in emerging markets, particularly in Asia and Latin America, presents opportunities for expanding diagnostic radioisotope production and access. This expansion can address healthcare inequalities and improve diagnostic capabilities in underserved areas.
• Investment in Low-Dose Imaging Technologies: Developing radioisotope imaging technologies that reduce radiation exposure presents a growth opportunity. These innovations can make diagnostic imaging safer, encouraging broader adoption for early and frequent diagnostics.

These strategic growth opportunities highlight the potential for innovation and market expansion in the diagnostic radioisotope sector. By focusing on PET imaging, hybrid systems, non-uranium isotope production, emerging markets, and low-dose technologies, companies can drive growth and improve patient outcomes.

Diagnostic Radioisotope Market Driver and Challenges

The diagnostic radioisotope market is influenced by various drivers and challenges that shape its growth and development. Understanding these factors is essential for navigating the market effectively.

The factors responsible for driving the diagnostic radioisotope market include:

• Rising Demand for Early Disease Detection: The growing emphasis on early detection of diseases like cancer and cardiovascular conditions is driving demand for diagnostic radioisotopes, particularly PET and SPECT isotopes.
• Technological Advancements in Imaging: Innovations in imaging technologies, such as hybrid systems and AI integration, are improving diagnostic accuracy, driving further adoption of radioisotope-based diagnostics.
• Global Aging Population: As the global population ages, the prevalence of chronic diseases increases, fueling the demand for diagnostic imaging procedures that rely on radioisotopes for early detection and monitoring.
• Increased Government Support: Governments worldwide are investing in nuclear medicine research and radioisotope production to ensure a stable supply of diagnostic isotopes, particularly in countries aiming for healthcare self-sufficiency.
• Growing Use of Non-Uranium Production: The shift toward non-uranium-based isotope production is gaining momentum, driven by environmental concerns and the desire to secure a stable supply chain for key isotopes like Technetium-99m.

Challenges in the diagnostic radioisotope market are:

• High Cost of Radioisotope Production: The cost of producing diagnostic radioisotopes, particularly through advanced methods like cyclotron production, can be prohibitive, limiting access in certain regions and affecting market expansion.
• Supply Chain Disruptions: The global supply chain for diagnostic isotopes can be fragile, with production disruptions affecting the availability of key isotopes like Technetium-99m, leading to delays in diagnostic procedures.
• Regulatory Hurdles: Strict regulatory requirements for the production, handling, and disposal of radioisotopes can slow down market growth, particularly in regions with complex nuclear regulations.

The diagnostic radioisotope market is driven by technological advancements, rising demand for early disease detection, and increasing government support. However, challenges such as high production costs, supply chain disruptions, regulatory hurdles, and limited access in emerging markets must be addressed. Balancing these drivers and challenges is key to sustaining growth in the market.

List of Diagnostic Radioisotope Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies diagnostic radioisotope companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diagnostic radioisotope companies profiled in this report include-

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler
• Nordion
• NTP Radioisotopes

Diagnostic Radioisotope by Segment

The study includes a forecast for the global diagnostic radioisotope market by radioisotope, imaging modality, application, end use, and region.

Diagnostic Radioisotope Market by Radioisotope [Analysis by Value from 2019 to 2031]:

• Technetium-99m
• Thallium-201
• Gallium-67
• Iodine-123
• FDG
• Rubidium-82
• Others

Diagnostic Radioisotope Market by Imaging Modality [Analysis by Value from 2019 to 2031]:

• SPECT
• PET
• Beta Emitters

Diagnostic Radioisotope Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnostic
• Therapeutic

Diagnostic Radioisotope Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Academic & Research Institutes
• Others

Diagnostic Radioisotope Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Diagnostic Radioisotope Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below image highlights recent developments by major diagnostic radioisotope producers in key regions: the USA, China, India, Japan, and Germany

• United States: The U.S. is advancing the production of Technetium-99m, the most widely used radioisotope in diagnostics. Recent developments include the establishment of non-uranium-based production facilities, which enhance the supply chain and reduce dependence on imported isotopes, ensuring a stable supply for medical imaging.
• China: China is increasing its capacity for radioisotope production, focusing on expanding the use of PET (Positron Emission Tomography) imaging. Recent developments include new cyclotrons to produce fluorodeoxyglucose (FDG) for PET scans, aimed at improving cancer diagnostics and broader healthcare access.
• Germany: In Germany, advancements in diagnostic radioisotope technologies focus on the development of hybrid imaging systems that combine PET with CT or MRI. These innovations improve diagnostic accuracy, particularly in oncology, cardiology, and neurology, enhancing patient outcomes through more precise imaging.
• India: India has made significant strides in self-sufficiency for radioisotope production, with the government investing in new research reactors. Recent developments include collaborations between hospitals and research institutions to increase the availability of radioisotopes for diagnostic purposes, particularly in rural and underserved areas.
• Japan: Japan is leveraging technological innovations to enhance the production and use of diagnostic radioisotopes. Recent developments focus on reducing radiation doses in medical imaging, improving patient safety while maintaining high imaging quality, especially in cancer detection and cardiovascular diagnostics.

Features of the Global Diagnostic Radioisotope Market

Market Size Estimates: Diagnostic radioisotope market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Diagnostic radioisotope market size by various segments, such as by radioisotope, imaging modality, application, end use, and region in terms of value ($B).

Regional Analysis: Diagnostic radioisotope market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotopes, imaging modalities, applications, end uses, and regions for the diagnostic radioisotope market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the diagnostic radioisotope market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the diagnostic radioisotope market by radioisotope (technetium-99m, thallium-201, gallium-67, iodine-123, FDG, rubidium-82, and others), imaging modality (SPECT, PET, and beta emitters), application (diagnostic and therapeutic), end use (hospitals, specialty clinics, diagnostic centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Diagnostic Radioisotope Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Diagnostic Radioisotope Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Diagnostic Radioisotope Market by Radioisotope
  • 3.3.1: Technetium-99m
  • 3.3.2: Thallium-201
  • 3.3.3: Gallium-67
  • 3.3.4: Iodine-123
  • 3.3.5: FDG
  • 3.3.6: Rubidium-82
  • 3.3.7: Others
• 3.4: Global Diagnostic Radioisotope Market by Imaging Modality
  • 3.4.1: SPECT
  • 3.4.2: PET
  • 3.4.3: Beta Emitters
• 3.5: Global Diagnostic Radioisotope Market by Application
  • 3.5.1: Diagnostic
  • 3.5.2: Therapeutic
• 3.6: Global Diagnostic Radioisotope Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Diagnostic Centers
  • 3.6.4: Academic & Research Institutes
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Diagnostic Radioisotope Market by Region
• 4.2: North American Diagnostic Radioisotope Market
  • 4.2.1: North American Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.2.2: North American Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.3: European Diagnostic Radioisotope Market
  • 4.3.1: European Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.3.2: European Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.4: APAC Diagnostic Radioisotope Market
  • 4.4.1: APAC Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.4.2: APAC Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.5: ROW Diagnostic Radioisotope Market
  • 4.5.1: ROW Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.5.2: ROW Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Diagnostic Radioisotope Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Diagnostic Radioisotope Market by Imaging Modality
  • 6.1.3: Growth Opportunities for the Global Diagnostic Radioisotope Market by Application
  • 6.1.4: Growth Opportunities for the Global Diagnostic Radioisotope Market by End Use
  • 6.1.5: Growth Opportunities for the Global Diagnostic Radioisotope Market by Region
• 6.2: Emerging Trends in the Global Diagnostic Radioisotope Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Diagnostic Radioisotope Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Diagnostic Radioisotope Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GE Healthcare
• 7.2: Siemens Healthineers
• 7.3: Koninklijke Philips
• 7.4: Cardinal Health
• 7.5: Lantheus Holdings
• 7.6: Bayer
• 7.7: Bracco
• 7.8: Eckert & Ziegler